Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells*

Subha Kannan, Marta De Santis, Matthias Lohmeyer, David J. Riese II, Gilbert H. Smith, Nancy Hynes, Masaharu Seno, Ralf Brandt, Caterina Bianco, Graziella Persico, Nicholas Kenney, Nicola Normanno, Isabel Martinez-Lacaci, Fortunato Ciardiello, David F. Stern, William J. Gullick, and David S. Salomon

Cripto-1 (CR-1), a recently discovered protein of the epidermal growth factor (EGF) family, was found to interact with a high affinity, saturable binding site(s) on HC-11 mouse mammary epithelial cells and on several different human breast cancer cell lines. This receptor exhibits specificity for CR-1, since other EGF-related peptides including EGF, transforming growth factor α, heparin-binding EGF-like growth factor, amphiregulin, epiregulin, betacellulin, or heregulin β that bind to either the EGF receptor or to other type 1 receptor tyrosine kinases such as erb B-3 or erb B-4 fail to compete for binding. Conversely, CR-1 was found not to directly bind to or to activate the tyrosine kinases associated with the EGFR, erb B-2, erb B-3, or erb B-4 either alone or in various pairwise combinations which have been ectopically expressed in Ba/F3 mouse pro-B lymphocyte cells. However, exogenous CR-1 could induce an increase in the tyrosine phosphorylation of 185- and 120-kDa proteins and a rapid (within 3–5 min) increase in the tyrosine phosphorylation of the SH2-containing adaptor proteins p66, p52, and p46 Shc in mouse mammary HC-11 epithelial cells and in human MDA-MB-453 and SKBr-3 breast cancer cells. CR-1 was also found to promote an increase in the association of the adaptor Grb2-guanine nucleotide exchange factor-mouse son of sevenless (mSOS) signaling complex with tyrosine-phosphorylated Shc in HC-11 cells. Finally, CR-1 was able to increase p42*38* mitogen-activated protein kinase (MAPK) activity in HC-11 cells within 5–10 min of treatment. These data demonstrate that CR-1 can function through a receptor which activates intracellular components in the ras/raf/MEK/MAPK pathway.

The human cripto-1 (CR-1) gene (also known as teratocarcinoma-derived growth factor-1 (TDGF-1)) is located on chromosome 3p21-3 and codes for a 28–36-kDa glycoprotein of 188 amino acids. CR-1 possesses an epidermal growth factor (EGF)-like consensus sequence that contains six cysteine residues in a region of approximately 37 amino acids (1). However, unlike other peptides within this family of growth factors that have a three-looped EGF-motif (designated A, B, and C) which are formed by three intramolecular disulfide bonds, the EGF-like repeat in CR-1 lacks an A loop and the B loop is truncated (2, 3). In addition, unlike most growth factors in the EGF family, the human CR-1 protein lacks a conventional hydrophobic signal peptide and a classical hydrophobic transmembrane domain (2). Nevertheless, recombinant human CR-1 protein is secreted when transiently expressed in Chinese hamster ovary cells (3). Refolded CR-1 peptides that correspond to the EGF-like repeat within the human CR-1 protein are mitogenic for nontransformed and malignant human and mouse mammary epithelial cells (3). Human CR-1 can also function as a dominant transforming gene in vitro in mouse NIH-3T3 fibroblasts and in mouse NOG-8 mammary epithelial cells (1, 4). CR-1 mRNA and immunoreactive CR-1 protein are differentially expressed in several human breast cancer cell lines, in approximately 80% of primary human infiltrating breast tumors and in 50% of ductal carcinomas in situ (5, 6).

Peptide growth factors that are members of the EGF family include transforming growth factor α (TGFα), amphiregulin (AR), heparin-binding EGF-like growth factor, betacellulin (BTC), epiregulin, and the neuregulin subfamily that consists

* From the Tumor Growth Factor Section, Laboratory of Tumor Immunology and Biology, NIC, National Institutes of Health, Bethesda, Maryland 20892, the ICRF Oncology Unit, Hammersmith Hospital, London, United Kingdom, the Department of Pathology, BML-350, Yale University School of Medicine, New Haven, Connecticut 06520-8023, the Friedrich Meischer-Institut, CH-4002 Basel, Switzerland, the Istituto Internazionale di Genetica e Biofisica, Naples, Italy, the Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, D. C. 20007, the Oncologia Sperimentale di Istituto Nazionale Per lo Studio e La Cur, Dei Tumori-Fondazione Pascale, Naples, Italy, and the Cattedra di Oncologia Medica, II Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, 80131 Naples, Italy

1 The abbreviations used are: CR-1, cripto-1; EGF, epidermal growth factor; TGFα, transforming growth factor α; AR, amphiregulin; HRG, heregulin; BTC, betacellulin; EGFR, EGF receptor; mSOS, mouse Son of Sevenless, guanine nucleotide exchange factor; MAPK, mitogen-activated protein kinase; erk, extracellular signal-regulated protein kinase; MEK, mitogen-activated erk-activating kinase; MBP, myelin basic protein; Shc, Src homologous and collagen protein; Grb2, growth factor receptor-bound protein; PAGE, polyacrylamide gel electrophoresis; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

* This work was supported in part by the National Cancer Institute, United States Public Health Service Grant CA-45708, and United States Army Medical Research and Material Command Grant DAMD-17-94-J-4476 (to D. F. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

* Supported by the National Cancer Institute, United States Public Health Service Grant HD-07149, and United States Army Medical Research and Material Command Grant DAMD-17-94-J-4036.

* Supported by the United States Army Medical Research and Material Command Grant DAMD-17-94-J-4498.

* To whom all correspondence and reprint requests should be addressed: Bldg. 10, RM 5339, Tumor Growth Factor Section, Laboratory of Tumor Immunology and Biology, NIC, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-9536; Fax: 301-402-8656; E-mail: davetgfs@helix.nih.gov.
of various isomers of α and β heregulin (HRG), gelial cell growth factors, and acetylcholine receptor inducing activity (7–10). The different neuregulins are derived by alternative splicing from a single gene. Peptides in the EGF family bind to and activate members of the erb B family of type 1 receptor tyrosine kinases. EGF, TGFα, AR, heparin-binding EGF-like growth factor, and epiregulin bind exclusively to the epidermal growth factor receptor (erb B/EGFR), whereas the neuregulin subfamily of peptides bind to c-erb B-3/HER-3 or c-erb B-4/HER-4 that can then heterodimerize and activate c-erb B-2/HER-2 following transphosphorylation (11–15). BTC can bind to either the EGFR or c-erb B-4. Since ligand-dependent activation of the EGFR receptor can also lead to heterodimerization with c-erb B-2, c-erb B-3, or c-erb B-4, this suggests that different pairs of heterodimers within the type 1 receptor tyrosine kinase family may contribute to the array of responses to various EGF-like ligands in a cell-specific and possibly ligand-specific manner by the recruitment of different combinations of intracellular signaling proteins (14). This apparent redundancy of different ligands and receptors may therefore contribute to signal diversification and amplification. One major pathway that is activated by a different EGF-like ligands through these type 1 receptor tyrosine kinases is the ras/rat/mitogen-activated protein kinase (MAPK) signal transduction pathway (16).

The HC-11 mouse mammary epithelial cell line is a clonal isolate originally derived from the COMMA-1D cell line, which was established from a midpregnant Balb/c mouse mammary gland (17). These cells express a number of mammary epithelial markers such as β-casein and express several distinct type 1 receptor tyrosine kinases, including the EGFR, c-erb B-2, and c-erb B-3 (17–20). In this context, HC-11 cells have been useful as an in vitro model system in which to define the intracellular signaling pathways that are engaged by EGF-related peptides that utilize these type 1 receptor tyrosine kinases and are involved in regulating proliferation and differentiation in mammary epithelial cells (19, 20). In the present study, we have attempted to define the intracellular signaling pathway that might be activated in HC-11 cells and in several different human breast cancer cell lines by a 47-mer refolded CR-1 peptide that corresponds in sequence to the EGF-like repeat of the human CR-1 protein (3). The CR-1 related peptide was found to bind to a unique specific, high-affinity receptor that is not the EGFR, erb B-2, erb B-3, or erb B-4. CR-1 was also found to enhance the tyrosine phosphorylation of the SH2-adaptor protein, Shc, and to promote the association of Grb2-mSOS intracellular signaling complex with tyrosine-phosphorylated Shc. These events were subsequently related to the downstream activation of the p42/44 MAPK isoform.

MATERIALS AND METHODS

Cell Culture and Growth—HC-11 mouse mammary epithelial cells were routinely grown in RPMI 1640 medium containing 8% heat-inactivated fetal bovine serum, 5 μg/ml bovine insulin (Sigma), and 10 ng/ml EGF (Collaborative Research, Watham, MA). Human breast cancer cell lines, MCF-7, ZR-75-1, T-47D, MDA-MB-231, MDA-MB-453, and SKBR-3 were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and insulin (10 μg/ml) as described previously (21). The Ba/F3 mouse pro-B lymphocyte cell line and clonal derivatives that express individual or pairs of type 1 receptor tyrosine kinases were generated as described previously (22, 23). Cells were treated with different concentrations of either refolded p47 CR-1 peptide that corresponds in sequence to the EGF-like motif in human CR-1 (3), recombinant human TGα, recombinant human HB-EGF, recombinant human BTC (R & D Systems, Inc.), recombinant mouse epiregulin (generously supplied by Toshi Komuraski, Taisho Pharmaceutical Co., Saitama, Japan), or recombinant human HRG β1-177-244 (generously supplied by Mark Slwikowski, Genentech, Inc., South San Francisco, CA).

Immunoprecipitation and Western Blot Analysis—Cells were grown until they were subconfluent and then propagated in serum-free medium containing human transferrin (10 μg/ml) and type 1V Pedersen fetuin (1 mg/ml) for 48 h. Cells were treated in serum-free medium with different concentrations of p47 CR-1 for various times and then lysed in 20 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 0.5% deoxycholate, 5 mM EDTA, 1% 2-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 20 mM sodium fluoride. In some cases the clarified protein lysates were either immunoprecipitated (0.5 mg/sample) with 2 μg of a rabbit anti-She antibody (Transduction Laboratories, Lexington, KY) or with 2 μg of anti-phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology, Inc.). Crude protein lysates (25 μg/sample) or immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose, blocked with 2% dry milk in Tris-buffed saline with 0.05% Tween 20, and incubated with a 1:1000 dilution of anti-Shc, anti-Grb-2, or anti-MOS monoclonal antibodies (Transduction Laboratories) or a 1:2000 dilution of the anti-phosphotyrosine monoclonal antibodies 4G10 and/or PY-20 (ICN Pharmaceuticals, Inc., Costa Mesa, CA). The bound mouse monoclonal antibodies were detected using a 1:5000 dilution of goat anti-mouse IgG conjugated to horseradish peroxidase (Amersham). Immunoreactive bands were detected by enhanced chemiluminescence (ECL, Amersham). erb B receptors were immunoprecipitated from recombinant Ba/F3 clonal derivatives using monospecific antisera as described previously (22).

MAPK Assays—A rabbit anti-MAPK antibody (Upstate Biotechnology, Inc., Lake Placid, NY) at a 1:10,000 dilution that recognizes both extracellular signal-regulated protein kinase erb-1 and erb-2 MAPK was used to detect activation of immunoreactive MAPK proteins by means of band shift following SDS-PAGE of crude cellular lysates as described previously (24). Bands were detected by the colorimetric NBT/BCIP system (Kirkgaard Perry Labs, Gaithersburg, MD). Alternatively, cells were lysed in buffer containing 1% Nonidet P-40, 0.5% deoxycholate, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM sodium orthovanadate, 2 μg/ml leupeptin, 2 μg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Lysates (100 μg/sample) were immunoprecipitated with an anti-erb-1 rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA). After 2 h, the immunoprecipitates were washed twice with lysis buffer followed by a final wash in kinase buffer containing 30 mM HEPES (pH 7.4), 10 mM MgCl2, 10 mM MnCl2, and 1 mM dithiothreitol. After the final wash, the immunoprecipitates were suspended in 30 μl of kinase buffer containing 5 μg of myelin basic protein (MBP) and 5 μl of (γ-32P)ATP (1000 Ci/mmol, Amersham) and incubated for 30 min at 37°C. The reaction was stopped with 2 × SDS sample buffer. The samples were then run on a 10% Tricine gel followed by autoradiography. The MBPs were quantified with a densitometer (Molecular Dynamics) (19).

Ligand Binding Assays—125I-p47 CR-1 peptide was prepared using IODO-GEN (Pierce Chemical Co.) in which 5 μg of peptide was labeled with 1 μCi of Na125I to a specific activity of 6–10 μCi/μg. Monolayers of HC-11 cells or human breast cancer cells in 12-well cluster dishes were washed in serum-free RPMI 1640 or Dulbecco’s modified Eagle’s medium containing 20 mM HEPES (pH 7.4) and 0.1% bovine serum albumin and treated in the same medium. Cells were incubated at 23°C for 2 h in 1 ml of binding buffer containing 3 × 106 cpm of 125I-p47 CR-1 in the absence or presence of increasing concentrations of unlabeled p47 CR-1 or with other EGF-related peptides. Cells were washed twice with phosphate-buffered saline and then solubilized in 1 ml of buffer containing 10 mM Tris-HCl (pH 8.0) and 0.5% SDS and counted in a γ-counter. The binding data were analyzed using the Ligand program to determine the Kd value as described (25).

RESULTS

Binding of CR-1 to HC-11 Mouse Mammary Epithelial Cells and Human Breast Cancer Cells—A 47-mer CR-1 refolded peptide that contains the EGF-like motif of human CR-1 is able to stimulate the proliferation and to inhibit β-casein expression in mouse HC-11 mammary epithelial cells. To determine if a high-affinity, specific binding site is expressed on HC-11 mammary epithelial cells that might mediate the biological effects of CR-1, HC-11 cells were incubated with 125I-p47 CR-1 in the absence or presence of increasing concentrations of unlabeled p47 CR-1. As illustrated in Fig. 1A, there is specific binding of the 125I-p47 CR-1 peptide to HC-11 cells with a Kd of approxi-


Fig. 1. Binding and competition curve of $^{125}$I-p47 CR-1. Binding of $^{125}$I-p47 CR-1 to HC-11 cells (A); inset, Scatchard plot of binding isotherm. B, competition of specific binding of $^{125}$I-p47 CR-1 to HC-11 cells by various concentrations of EGF (○), AR (□), TGFα (●), HRGβ1 (▲), or p47 CR-1 (●). C, MDA-MB-231 human breast cancer cells were treated with 25 μg/ml anti-EGFR monoclonal antibody or 25 μg/ml anti-erb B-2 TAb 250 monoclonal antibody and specific binding of $^{125}$I-p47 CR-1 (10 ng/ml) was determined.

approximately 96 nM (Fig. 1A, inset). Various concentrations of EGF, TGFα, AR, or HRGβ1 were unable to compete for binding with $^{125}$I-p47 CR-1 on HC-11 cells (Fig. 1B). Likewise, heparin-binding EGF-like growth factor, epiregulin, or BTC were ineffective in blocking the binding of the $^{125}$I-p47 CR-1 peptide (data not shown). This potential receptor is not unique to HC-11 mouse mammary epithelial cells since $^{125}$I-p47 CR-1 also binds specifically and with high affinity to several estrogen receptor positive (MCF-7, T47-D, and ZR-75–1) and to estrogen receptor negative (MDA-MB-231, MDA-MB-453 and SKBr-3) human breast cancer cell lines that exhibits comparable specificity for CR-1 binding as in mouse HC-11 cells (Table I). Moreover, blocking the EGFR receptor on MDA-MB-231 human breast cancer cells with 25 μg/ml of the 528 anti-EGFR monoclonal blocking antibody which is sufficient to impede $^{125}$I-EGF binding (26) does not lead to any change in the specific binding of $^{125}$I-p47 CR-1 to these cells (Fig. 1C), confirming the observation that CR-1 does not directly bind to the EGFR (3). In addition, the binding of $^{125}$I-p47 CR-1 peptide to MDA-MB-231 cells or SKBr-3 cells (data not shown) is unaffected by the anti-erb B-2 TAb 250 blocking monoclonal antibody.

CR-1 Fails to Directly Activate erb B Family Receptor Tyrosine Phosphorylation in Recombinant Ba/F3 Cells—Parental Ba/F3 mouse pro-B lymphocytes express low levels of endogenous erb B-3 but do not express EGFR, erb B-2, or erb B-4. Ba/F3 clones have been genetically engineered to ectopically express either EGFR, erb B-2, erb B-3, or erb B-4 type 1 receptor tyrosine kinases either alone or in different pairwise combinations (22, 23). These recombinant cell lines have been particularly useful in defining different homodimeric and heterodimeric combinations of the type 1 receptor kinases that can bind to various ligands within the EGF family of peptides (23). Since CR-1 is structurally related in part to this family of peptides, the 47-mer CR-1 refolded peptide and an Sf9-derived recombinant human GST-CR-1 fusion protein3 were tested for their ability to directly bind and stimulate receptor tyrosine phosphorylation in single recombinant Ba/F3 derivatives that are expressing different erb B family members (Fig. 2). p47 CR-1 was unable to significantly modify EGFR (Fig. 2A), erb B-2/neu/HER-2 (Fig. 2B), erb B-3/HER-3 (Fig. 2D), or erb B-4/HER-4 (Fig. 2C) tyrosine phosphorylation in Ba/F3 clones that were expressing these tyrosine kinases. In contrast, BTC was able to stimulate EGFR and erb B-4 phosphorylation (Fig. 2, A and C) while HRGβ1 was able to indirectly stimulate erb B-2 phosphorylation (Fig. 2B) by binding to endogenous erb B-3 (22). p47 CR-1 was also ineffective in modulating the tyrosine phosphorylation of these different type 1 receptor tyrosine kinases in Ba/F3 cells that were expressing different pairs of erb B receptors demonstrating that CR-1 does not directly bind to heterodimers within this family of receptor tyrosine kinases (data not shown). Similar negative results on tyrosine receptor phosphorylation in either single or double erb B expressing recombinant Ba/F3 clones were obtained after treatment of

| Cell line | n M  | Sites/cell |
|----------|------|------------|
| HC-11    | 96   | 3.9 × 10^5 |
| MDA-MB-453 | 80   | 4.4 × 10^5 |
| MDA-MB-231 | 33   | 1.8 × 10^5 |
| SKBr 3   | 78   | 4.5 × 10^5 |
| ZR-75–1  | 61   | 1.1 × 10^5 |
| T47-D    | 50   | 1.4 × 10^5 |
| MCF-7    | 26   | 5.3 × 10^4 |

3. M. Seno, manuscript in preparation.
three of these cells with the full-length Sf9 recombinant GST-human CR-1 fusion protein.

CR-1 Stimulates Tyrosine Phosphorylation of Shc and Activates MAPK in HC-11 Mammary Epithelial Cells and in Human Breast Cancer Cells—Although CR-1 does not directly activate any known type 1 receptor erb B tyrosine kinase, its receptor may still consist of a membrane-associated tyrosine kinase or alternatively the receptor may associate with an additional cytoplasmic or membrane bound tyrosine kinase to generate a signal. To determine if the p47 CR-1 peptide could modulate the tyrosine phosphorylation of other proteins in HC-11 cells, serum-starved cells were treated with p47 CR-1 for 5 min and cell lysates were immunoprecipitated with 4G10 mouse monoclonal anti-phosphotyrosine antibody. Immunoprecipitates were then electrophoresed and probed by Western blot analysis with the PY-20 mouse monoclonal anti-phosphotyrosine antibody (Fig. 3A). An increase in tyrosine phosphorylation of a 185-kDa protein was observed. A similar CR-1-induced increase in the tyrosine phosphorylation of a 185-kDa protein was also observed in other cells that were capable of binding -1, p47 CR-1 such as MDA-MB-453, SKBr3, and T47-D human breast cancer cells after immunoprecipitation and Western blotting with anti-phosphotyrosine antibodies (data not shown). The identity of the p185 phosphoprotein has not yet been identified.

She is an SH-2 containing adaptor protein that exists as three distinct isoforms of 66, 52, and 46 kDa and that becomes tyrosine-phosphorylated after ligand activation of several different type 1 receptor tyrosine kinases (27–29). Cell lysates from p47 CR-1-treated serum-starved HC-11 cells exhibited a time-dependent increase in the tyrosine phosphorylation of the p66 Shc and p46 Shc isoforms, which could be detected following immunoprecipitation with an anti-Shc antibody and subsequent screening in Western blot analysis with anti-phosphotyrosine antibodies (Fig. 3, B and C). In HC-11 cells which had been sufficiently serum-starved, the increase in phosphorylation of p46 Shc (Fig. 3B) and p66 Shc (Fig. 3C) in response to p47 CR-1 was transient with an 8-fold increase in p46 Shc phosphorylation being observed after 5–7 min, which decreased to control levels after 10 min of treatment (Figs. 3B and 5B). No significant changes in the phosphorylation of the p52 isoform of Shc were detected in HC-11 cells. A less dramatic but measurable increase in the tyrosine phosphorylation of either p52 and/or p46 Shc could also be detected in either MDA-MB-453 or SKBr3 human breast cancer cells after treatment with either the p47 CR-1 peptide (Fig. 3C) or the GST-CR-1 recombinant fusion protein (data not shown). Proteins of 185 and 120 kDa that were also tyrosine-phosphorylated in a transient manner were detected in the Shc immunoprecipitates after probing the Western blots with a mixture of two different anti-phosphotyrosine monoclonal antibodies (Fig. 3C). These proteins were found to co-immunoprecipitate with Shc after stimulation of HC-11, MDA-MB-453, or SKBr3 cells with p47 CR-1. The identity of these two proteins has not been determined.

She is an adapter protein that can bind to specific consensus sequences which contain phosphotyrosine residues in the COOH terminus of several different tyrosine kinase receptors through either an SH2 domain or a phosphotyrosine-binding domain (29). In turn, binding of phosphorylated Shc to the SH2 domain of Grb2 through the tyrosine-phosphorylated collagen homology domain of Shc can link a number of different growth factor receptor tyrosine kinases to the ras/raf/MEK/MAPK signaling pathway since Grb2 is intrinsically complexed with the ras guanine nucleotide exchanger, SOS (27, 29). To ascertain if p47 CR-1 could facilitate the association of the Grb2-mSOS complex with phosphorylated Shc in mammary epithelial cells, HC-11 cell lysates were immunoprecipitated with the Shc antibody and immunoblotted with either an anti-Grb2 (Fig. 4A) or an anti-SOS (Fig. 4B) antibody. In both cases, p47 CR-1-induced a time-dependent increase in the association of Grb2 and mSOS with phosphorylated Shc. Activation of p21ras by SOS can ultimately lead to the downstream activation of mitogen-activated, erk-activating kinase (MEK) through raf and the subsequent stimulation of MAPK activity (16, 30). To ascertain if p47 CR-1 could stimulate MAPK activity, serum-starved HC-11 cells were treated for different times with the peptide, and cell lysates were electrophoresed and probed with an anti-MAPK antibody that detects both MAPK isoforms, p44erk-1 and p42erk-2 (Fig. 5A). Alternatively, cell lysates were immunoprecipitated with an anti-MAPK antibody and utilized in an in vitro kinase assay with MBP as a substrate to quantify total MAPK activity (Fig. 5B). The p47 CR-1 peptide produced a rapid tyrosine phosphorylation of p42erk-2 within 3–5 min that could be detected by the presence of a slower migrating band that represents the phosphorylated form of p42erk-2 (Fig. 5A). Phosphorylation of this species of p42erk-2 peaked at 7 min and subsequently declined. A nearly 4-fold increase in phosphorylation of the MAPK substrate, MBP, was also observed and found to have identical kinetics in response to p47 CR-1 treatment and was delayed relative to the increase in p46 Shc phosphorylation (Fig. 5B).

**DISCUSSION**

EGF, TGFα, AR, and HRGβ1 stimulate the growth and regulate the differentiation of normal and malignant mouse and human mammary epithelial cells in vitro (7, 11, 31–34). However, the role of other EGF-related peptides in regulating the growth and differentiation of mammary epithelial cells has not been fully explored. This may be particularly important since only a subset of peptides within the EGF family bind exclu-
sively to the EGFR. Additional proteins in this family, such as the neuregulin subfamily which include the HRGs, bind to other members of the type 1 receptor tyrosine kinase family of receptors such as c-erb B-3 or c-erb B-4, that can then heterodimerize and activate c-erb B-2 following transphosphorylation (3–15, 31, 34–36). Finally, BTC can equally activate either the EGFR or c-erb B-4 (23). Since ligand-dependent activation of the EGFR receptor can also lead to heterodimerization with c-erb B-2, c-erb B-3, or c-erb B-4, this suggests that different combinatorial pairs of heterodimers within the type 1 receptor tyrosine kinase family may contribute in a hierarchical fashion through signal diversification to the array of responses that are produced to various EGF-like ligands in a cell-specific manner (14, 15, 35, 36).

The present study is the first to demonstrate that a refolded peptide which corresponds in sequence to the EGF-like motif of the human CR-1 protein can bind to a unique receptor that can modify the tyrosine phosphorylation of different proteins which are components in the ras/raf/MEK/MAPK pathway. CR-1 is a newly discovered member of the EGF family of peptides that is structurally unique within this family as CR-1 lacks an A loop and possesses a truncated B loop (2, 3, 7). Since conserved amino acid residues in the A loop in conjunction with residues in the C loop are necessary for peptide binding to the EGFR receptor (37) and since the 47-mer refolded CR-1 related peptide does not directly compete with EGF for binding to the EGFR (3), this demonstrates that CR-1 cannot bind to this receptor. Nevertheless, CR-1 is able to stimulate the proliferation and differentiation of HC-11 cells and the growth of several different nontransformed human mammary epithelial and breast cancer cell lines suggesting that a receptor exists for this peptide (3). In this context, the synthetic CR-1 peptide interacts with a high-affinity binding site on HC-11 mouse mammary epithelial cells and on several different human breast cancer cell lines that exhibit specificity for the CR-1 47-mer peptide since other EGF-related peptides that bind either to the EGFR or c-erb B-3 and c-erb B-4 fail to compete for binding with the labeled p47 CR-1 peptide. This suggests that the CR-1-binding site is unique. Conversely, the CR-1 peptide or recombinant GST-CR-1 fusion protein does not directly activate the tyrosine kinase of either the EGFR or other members of the type 1 receptor tyrosine kinase family either alone or in various heterodimeric combinations in mouse Ba/F3 cells (22, 23). Nevertheless, the ability of 47-mer CR-1 peptide to induce the tyrosine phosphorylation of 185- and 120-kDa proteins in HC-11 mouse mammary epithelial cells and MDA-MB-453 or SKBr-3 human breast cancer cells suggests that CR-1 binds to a potential receptor that has either an intrinsic tyrosine kinase.

**FIG. 3.** Tyrosine phosphorylation of Shc after CR-1 treatment. Serum-starved HC-11 (A–C) or MDA-MB-453 or SKBr-3 human breast cancer cells (C) were treated without or with 100 ng/ml p47 CR-1 for 5 min. A, lane 2, or various times indicated (B and C). The cell lysates were immunoprecipitated with anti-phosphotyrosine (4G10, Upstate Biotechnologies) antibody (A) or a polyclonal anti-Shc antibody (B and C). The immunoprecipitates were resolved on a 8–16% SDS-PAGE gel and immunoblotted with a PY20 antibody (A and B, upper panel) or a mixture of PY20 and 4G10 antibodies (C). The lower panels in B and C represent the same blots stripped and reprobed with monoclonal anti-Shc antibody to demonstrate that equal amounts of Shc are present in all lanes.

**FIG. 4.** Enhanced Grb2-mSOS association with Shc upon CR-1 stimulation in HC-11 cells. HC-11 cells were treated without or with p47 CR-1 (100 ng/ml) for various times. The cell lysates were immunoprecipitated with polyclonal anti-Shc antibody and analyzed by Western blotting using an anti-Grb2 (A) or anti-mSOS (B) antibody.
Cripto-1 Activates Shc and MAPK

 activity or that associates with a tyrosine kinase. In this context, it is known that various members of the type 1 receptor tyrosine kinase family can heterodimerize following ligand binding or associate with p60src. Heterodimerization might facilitate the activation of different signaling proteins thereby contributing to signal amplification and diversification in response to different type 1 receptor ligands (14, 15, 36). The present experiments do not formally exclude the possibility that the CR-1 receptor can also heterodimerize with one of these type 1 receptor tyrosine kinases or with other soluble src-related tyrosine kinases and that these interactions may be essential for propagation of an intracellular signal.

The present data also demonstrates that p47 CR-1 treatment of HC-11, MDA-MB-453, or SKBr-3 cells can lead to a rapid increase in tyrosine phosphorylation of the p66, p52, and p46 isoforms of Shc which can then associate with the Grb2-mSOS signaling complex. Since this is one possible mechanism by which other growth factor receptor tyrosine kinases can couple to the MEK/MAPK pathway through ras and raf (27–30, 38), these results may be functionally significant with respect to defining components in the intracellular signal transduction pathway that are activated by the CR-1 receptor. Moreover, the results demonstrate that CR-1 can activate p42MAPK by rapidly inducing the tyrosine phosphorylation of this MAPK isoform. Since activation of MAPK by various growth factors appears in certain cells to be obligatory for cell proliferation and/or for differentiation (16), then this same situation may also be applicable to CR-1 in its ability to stimulate growth and modulate the expression of β-casein and whey acidic protein in HC-11 cells and in primary mouse mammary epithelial cells in response to lactogenic hormones such as prolactin. Identification and characterization of the CR-1 receptor following chemical cross-linking of its ligand should clarify some of these issues. In this respect, attempts to chemically cross-link the 125I-p47 CR-1 peptide have been unsuccessful. However, we have recently expressed a full-length, refolded, biologically active human CR-1 protein in Escherichia coli and in Sf9 insect cells with a baculovirus expression vector. Cross-linking of these proteins to appropriate target cells such as HC-11 should now be feasible.

REFERENCES

1. Ciccodicola, A., Dono, R., Obici, S., Simeone, A., Zollo, M., and Persico, M. G. (1989) EMBO J. 8, 1987–1991
2. Dono, R., Montuori, N., Rocchi, M., De Penti-Zilli, L., Ciccodicola, A., and Persico, M. G. (1989) EMBO J. 8, 2313–2320
3. Brandt, R., Normanno, N., Gullick, W. J., Lin, J.-H., Harkins, R., Schneider, D., Jones, B.-W., Ciardiello, F., Persico, M. G., Armenante, F., Kim, N., and Salomon, S. (1994) J. Biol. Chem. 269, 17320–17328
4. Ciardiello, F., Dono, R., Kim, N., Persico, M. G., and Salomon, D. S. (1991) Cancer Res. 51, 1051–1054
5. Qi, C.-P., Liscia, D. S., Normanno, N., Merlo, G., Johnson, G. R., Gullick, W. J., Ciardiello, F., Saeki, T., Brandt, R., Kim, N., Kenney, N., and Salomon, D. S. (1994) Br. J. Cancer 69, 903–910
6. Dublin, E. A., Bower, L. G., Barnes, D. M., and Gullick, W. J. (1995) Int. J. Oncol. 7, 617–622
7. Normanno, N., Ciardiello, F., Brandt, R., and Salomon, D. S. (1994) Breast Cancer Res. Treat. 29, 11–27
8. Mudge, A. W. (1995) Curr. Biol. 3, 361–364
9. Watanabe, T., Shintani, A., Nakata, M., Shing, Y, Folkman, J., Igarashi, K., and Sasada, R. (1994) J. Biol. Chem. 269, 9966–9973
10. Toyoda, H., Komura, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and Hanada, K. (1995) J. Biol. Chem. 270, 7495–7500
11. Karunagaran, D., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. (1995) J. Biol. Chem. 270, 9993–9999
12. Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., and Yoshinaga, S. K. (1996) J. Biol. Chem. 271, 3884–3890
13. Cohen B. D., Green, J. M., Foy, L., and Fell H. P. (1996) J. Biol. Chem. 271, 4813–4818
14. Pinkas-Kramarski, R., Soussan, L., Waterman, Levkowitz, G., Abroy, I Klaipper, L., Lavi, S., Segre, R., Ratzkin, B. J., Seala, M., and Yarden, Y (1996) EMBO J. 15, 2452–2467
15. Beeri, R. E., and Hynes, N. E. (1996) J. Biol. Chem. 271, 6071–6076
16. Marshall, C. J. (1995) Cell 80, 179–185
17. Hynes, N. E., Taverna, D., Harwether, I. M., Ciardiello, F., Salomon, D. S., Yamamoto, T., and Groen, B. (1996) Mol. Cell. Biol. 16, 4027–4034
18. Taverna, D., Groen, B., and Hynes, N. E. (1991) Cell Growth Diff. 2, 145–154
19. Marte, B. M., Graus-Porta, D., Jeschke, M., Fabbro, D., Hynes, N. E., and Taverna, D. (1995) Oncogene 10, 167–175
20. Marte, B. M., Jeschke, M., Graus-Porta, D., Taverna, D., Hofer, P., Groen, B., Yarden, Y., and Hynes, N. E. (1995) Mol. Endocrinol. 9, 14–23
21. Normanno, N., Qi, C.-F., Gullick, W. J., Persico, G., Yarden, Y., Wen, D., Plowman, G., Kenney, N., Johnson, G., Kim, N., Brandt, R., Martinez-Luca, I., Dickson, R. B., and Salomon, D. S. (1995) Int. J. Oncol. 6, 903–911
22. Riese, D. J., Van Raaij, T. M., Plowman, G. D., Andrews, G. C., and Stern, D. F. (1995) Mol. Cell. Biol. 15, 5770–5776
23. Riese, D. J., Bermingham, Y., Van Raaij, T. M., Buckley, S., Plowman, G. D., and Stern, D. F. (1996) Oncogene 12, 345–353
24. Ray, L. B., and Sturgill, T. W. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 3753–3757
25. Munson, P. J., and Rodbard, D. (1980) Anal. Biochem. 107, 220–239
26. Baserga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K. Miller, W. H., and Mendelsohn, J. (1993) J. Natl. Cancer Inst. 85, 1327–1333
27. Pelici, G., Lanfrancone, L., Salcini, A. E., Romano, A., Mole, S., Borello, M. G., Segatto, O., Di Fiore, P. P., and Pelici, P. G. (1995) Oncogene 11, 899–907
28. Ravichandran, K. S., Lorenz, U., Shoeison, S. E., and Burakoff, S. J. (1995) Mol. Cell. Biol. 15, 593–600
29. Ratzer, A. G., Blakie, P., Nelson, K., Schlessinger, J., and Margolis, B. (1995) Mol. Cell. Biol. 15, 4403–4409
30. Sasaoka, T., Langlois, W. J., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 32621–32625
31. Peles, E., and Yarden, Y. (1993) BioEssays 15, 815–824
32. Lin, C. Q., Dempsey, P. J., Coffey, R. J., and Bissell, M. J. (1995) J. Cell Biol. 129, 1115–1126
33. Yang, Y., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G., Weidner, R. M., Birchmeier, C., and Birchmeier, W. (1995) J. Cell Biol. 131, 215–226
34. Normanno, N., Selvam, M. P., Qi, C.-F., Saeki, T., Johnson, G., Kim, N., Ciardiello, F., Shoyab, M., Plowman, G., Brandt, R., Todaro, G., and Salomon, D. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2790–2794
35. Carraway, K. L., and Cantley, L. C. (1994) Cell 78, 5–8
36. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. (1995) Breast Cancer Res. Treat. 35, 115–132
37. Groen, L. C., Nice, E. C., and Burgess, A. W. (1994) Growth Factors 11, 235–257
38. Quilliam, L. A., Khosravi-Far, R., Huff, S. Y., and Der, C. J. (1995) BioEssays 17, 395–404